Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells

Sabry M. Attia1,2*, Sheikh F. Ahmad1, Mushtaq A. Ansaria1, Ahmed Nadeem1, Othman A. Al-Shabanah1, Mohammed M. Al-Harbi1, Saleh A. Bakheet1

1 Pharmacology and Toxicology Department, Faculty of Pharmacy, King Saud University, 11451, Riyadh, Saudi Arabia, 2 Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt

* attiasm@yahoo.com, attiasm@ksu.edu.sa

Abstract

Dexrazoxane has been approved to treat anthracycline-induced cardiomyopathy and extravasation. However, the effect of dexrazoxane on epirubicin-induced genetic alterations in germ cells has not yet been reported. Thus, the aim of this study was to determine whether dexrazoxane modulates epirubicin-induced genetic damage in the germ cells of male mice. Our results show that dexrazoxane was not genotoxic at the tested doses. Furthermore, it protected mouse germ cells against epirubicin-induced genetic alterations as detected by the reduction in disomic and diploid sperm, spermatogonial chromosomal aberrations, and abnormal sperm heads. The attenuating effect of dexrazoxane was greater at higher dose, indicating a dose-dependent effect. Moreover, sperm motility and count were ameliorated by dexrazoxane pretreatment. Epirubicin induced marked biochemical changes characteristic of oxidative DNA damage including elevated 8-hydroxy-2′-deoxyguanosine levels and reduction in reduced glutathione. Pretreatment of mice with dexrazoxane before epirubicin challenge restored these altered endpoints. We conclude that dexrazoxane may efficiently mitigate the epirubicin insult in male germ cells, and prevent the enhanced risk of abnormal reproductive outcomes and associated health risks. Thus, pretreating patients with dexrazoxane prior to epirubicin may efficiently preserve not only sperm quality but also prevent the transmission of genetic damage to future generations.

Introduction

Anthracyclines are highly effective against mesenchymal malignancies and epithelial tumors [1]. They include numerous chemotherapeutic agents, for example doxorubicin and its analog epirubicin (4′-epidoxorubicin), which differs from doxorubicin in the steric position of the 4′-OH group. Epirubicin is generally used because it has an equivalent antitumor spectrum of action to that of doxorubicin but shows lesser cardiac and systemic toxicity than doxorubicin [2]. Similar to other anthracyclines, epirubicin acts by intercalating DNA strands, which
induces complex formation and further prevents RNA and DNA synthesis. Epirubicin also triggers DNA cleavage by DNA topoisomerase II, thereby activating mechanisms that lead to cell damage. In addition, epirubicin produces free radicals that cause DNA and cell damage [3].

Similar to other anti-cancer agents, high doses of anthracyclines induce programmed cell death [3]. Furthermore, several lines of evidence show that low doses of anticancer agents induce mitotic catastrophe resulting from abnormal mitotic events of improper chromosomal separation and cell division [4]. Epirubicin has been reported to cause genetic damage in animals and humans [5–8]. Such damage can give rise to secondary malignancies in somatic cells. However, when germ cells are affected, the genetic damage can not only affect sperm quality but can also induce genetic hazards to future generations [9]. Numerical chromosomal aberrations such as diplody and disomy in gametes are the most common causes of fetal loss and fertility impairment in humans [10, 11]. In newborns, numerical chromosomal aberrations are a frequent cause of congenital defects and mental retardation such as Down's syndrome. Moreover, more than 35% of spontaneous abortions are due to numerical chromosomal aberrations, and the most common cases are those with XO constitution and trisomies of chromosomes 16, 21, and 22 [12]. Syndromes involving additional or missing sex chromosomes carry fewer severe morphological defects but are associated with drastically impaired fertility [13].

Dexrazoxane is approved to protect the skin and heart from anthracycline-induced extravasation and cardiotoxicity [14, 15]. Cells cleave dexrazoxane during regular metabolism, generating an ethylenediaminetetraacetic acid derivative that chelates iron to decrease oxidative stress, thereby activating the cellular mechanism that protects the heart from acute anthracycline-induced injury [16, 17]. Importantly, dexrazoxane has not been shown to inhibit the antitumor effects of anthracyclines in pediatric patients with leukemia, or those patients with breast cancer, and does not increase the risk for development of secondary tumors [18, 19]. A possible explanation for this apparent contradiction was provided in a set of mechanistic experiments by Yan et al. [20], which suggested that dexrazoxane protected normal but not tumor cells. This study demonstrated that while dexrazoxane blocked anthracycline-induced double-stranded DNA breaks in HTETOP cells, it did not inhibit doxorubicin-induced programmed cell death that occurred via reduced glutathione (GSH) depletion in a topoisomerase II-independent manner [20].

Despite the intensive use of dexrazoxane in epirubicin-induced extravasation and heart failure, no information is available in the literature on its potential to induce genetic damage in germ cells. Therefore, evaluation of the effects of co-treatment with dexrazoxane and epirubicin on genetic alterations in the germ cells is important to obtain more insights into the genetic alterations induced by epirubicin that may play a role in the occurrence of the reproductive toxicity. In this study, a series of related but distinct cytogenetic techniques were used, including sperm fluorescence in situ hybridization (FISH) method and spermatogonial metaphase chromosomal analysis, to determine genetic damage in the germ cells. Epididymal sperm analysis after exposure to dexrazoxane, epirubicin, or both was performed to assess the influence of this combination on sperm quality. Moreover, the total testis and epididymal sperm levels of GSH and DNA 8-hydroxy-2ʹ-deoxyguanosine (8-OHdG), indicators of DNA oxidative stress, were measured as a possible mechanism underlying this mitigation.

Materials and Methods

Animals

Adult male Swiss albino mice, aged 9–11 weeks and weighing 18–24 g were acquired from the animal house, Faculty of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Mice were kept in our smaller animal house for one week under standard conditions of humidity, light (12 h light/dark cycle), and temperature (24 ± 3°C). Mice were fed standard mice chow and water *ad libitum*. All procedures conducted with the mice were in accordance with the standards in the guidelines for the care and use of experimental animals. The study protocol was approved by the Animal Ethics Committee of the Faculty of Pharmacy, King Saud University. The vehicle control and treatment groups consisted of five randomly assigned mice each.

**Drugs and treatment**

Epirubicin and dexrazoxane, which were obtained from Sigma-Aldrich (St. Louis, MO, USA), were dissolved in dimethyl sulfoxide (DMSO, 10%) in normal saline and were injected intraperitoneally within 1 h following preparation. The experimental design of the epirubicin and dexrazoxane treatment, sampling times, and the assessed parameters are schematically shown in Fig 1. Epirubicin was injected at doses of 3–12 mg/kg, which were selected based on previous clastogenic and aneugenic studies in mice [6, 7]. Dexrazoxane at 75 and 150 mg/kg has previously shown promising protection against genomic damage induced by podophyllotoxins in mice [21–23] and epirubicin-induced genetic damage in mice bone marrow cells [24]. Furthermore, the selected doses are within the chemotherapeutic dose range for humans. The control mice were injected with the same amounts of DMSO in normal saline.

**Sperm FISH assay**

The sperm FISH assay was used to determine the frequency of aneuploidy during meiotic divisions of spermatocytes. Animals were euthanized by cervical dislocation 23 days after the injection of epirubicin, dexrazoxane, or both, and then sperm were isolated from the *cauda*...
epididymis. Sperm sampling time was based on the published timeline of the 5-bromo-2'-deoxy-
yuridine (BrdU)-incorporation assay for epirubicin [7]. The BrdU-incorporation assay data
demonstrate that epirubicin induced a significant prolongation of meiotic divisions in mouse
spermatocytes [7]. In the epididymal sperm analysis, a crucial prerequisite for the timing of
sperm sampling is a precise knowledge of both duration of meiotic stages and possible tempo-
ral changes of meiotic divisions induced by the chemical aneugen. Schmid et al. [25] suggest
that the influence of a test chemical on meiotic cell cycle progression should be determined
before designing sampling time of sperm cells in order to optimize the test protocol and to
avoid missing an effect by inappropriate timing of the sperm samples.

The frequencies of diploid and disomic sperm cells were assessed by sperm FISH assay with
DNA probes specific for mouse chromosomes 8, Y, and X, in which each probe was labeled
with a different color. The hybridization, washing, and amplification of the signals were carried
out as described previously [26]. The sperm cells were examined for aneuploidy using a Nikon
fluorescence microscope. Fluorescence signals from coded slides were scored in approximately
10000 sperm cells per animal, and the sperm cells were classified as normal (Y8 and X8), dip-
loid (XX88, YY88, and XY88), or disomic (XY8, X88, and Y88) (Fig 2).

Spermatogonial metaphase chromosomal analysis

In the spermatogonial metaphase chromosomal analysis that was performed 20 h post-treat-
ment with epirubicin, dexrazoxane, or both, the mice were intraperitoneally treated with 4 mg/
kg colchicine. The mice were euthanized 4 h later, the testes separated, and then the slides pre-
pared as described previously [27]. Briefly, the separated testes were washed with 2.2% tri-
sodium citrate, and then the seminiferous tubules were teased-out and soaked in 1% tri-sodium
citrate solution at room temperature for 20 min. The solution was removed completely, and
the tubules were suspended in Carnoy’s fixative (methanol/glacial acetic acid, 3 + 1). The fixa-
tive was changed three times and the tubules were then dispersed with Pasteur pipettes in 50%
glacial acetic acid to obtain spermatogonia. After centrifugation, the pellets were suspended in
fresh fixative and 2–3 drops of the cell suspension were put on a microscopic slide, which had

Fig 2. Representative images of various signal combinations in epididymal sperm. X8 and Y8, XY8 to
X88, and XX88 are normal, disomic, and diploid sperm, respectively. Sperm were hybridized with DNA
probes specific for chromosomes X (yellow signal with fluorescein isothiocyanate (FITC and CY3), Y (green
signal with FITC), and B (red signal with CY3).

doi:10.1371/journal.pone.0163703.g002
been wetted with 70% ethanol and flame dried. The slides were then stained with 5% Giemsa and had cover slips affixed using Eukitt mounting medium.

Strict scoring criteria were used to distinguish chromosome complements to avoid misinterpreting the data. First, slides were screened for regions of suitable technical quality, where the metaphase chromosomes were well spread. The types of aberrations recorded included chromatid/chromosome breaks, chromatid/chromosome gaps, and fragments [27]. Breaks were true discontinuities with clearly dislocated fragments. They were distinguished from achromatic lesions (gaps), which do not represent true discontinuities in the DNA. It is generally assumed that gaps are sites of despiralisation in the metaphase chromosome, which render the DNA invisible under light microscopy. It has been proposed that an achromatic lesion may actually be a single-strand break in the DNA double helix because of incomplete excision repair and thus may represent a point of possible instability [28]. Therefore, gaps are always noted but reported separately from true chromosomal aberrations. Approximately 500 well-spread spermatogonial metaphases from each group were investigated, and the percentage of total structural chromosomal aberrations was recorded. The average aberrations/100 spermatogonial metaphases, excluding gaps (due to their controversial genetic significance), were calculated. Fig 3 shows an example of spermatogonial metaphase with a structural chromosomal aberration.

**Epididymal sperm analysis**

Sperm cells from the same animals that were euthanized for the sperm FISH assay were also evaluated for sperm parameters. Specifically, total sperm number and motility were determined using a bright field microscope with a Neubauer-hemocytometer according to the World Health Organization (WHO) guide as previously described [29]. For sperm morphology, aliquots of sperm suspensions were stained with eosin-Y (1%), smeared on glass slides, air-dried, and fixed to make them permanent. Coded slides were then examined by a light microscope, and the abnormal morphologies were classified as closely to those previously described [30]. About 500 sperm cells per mouse were evaluated for morphological abnormalities such as banana-shaped, hookless, amorphous, and tail abnormalities (Fig 4).

![Fig 3. Spermatogonial metaphase with a structural chromosomal aberration: fragment (arrow).](doi:10.1371/journal.pone.0163703.g003)
Measurement of 8-OHdG and GSH levels

To study the influence of dexrazoxane on DNA oxidative damage induced by epirubicin, two separate experiments were performed. In the first experiment, mice were euthanized 24 h after treatment with epirubicin (with or without dexrazoxane pretreatment) and their testes isolated. In the second experiment, mice were euthanized 23 days after treatment with epirubicin (with or without dexrazoxane pretreatment) and their sperm cells isolated. In both experiments, testicular and sperm DNA were isolated using DNA Extractor WB (Wako Chemicals, USA), the isolated DNA was digested with DNase-1, and then 8-OHdG levels were measured using the Bioxytech 8-OHdG enzyme-linked immunosorbent assay kit (ELISA) kit (OXIS Health Products) as described previously [31]. The stated values were the means of triplicate measurements, and 8-OHdG levels are presented as ng/μg DNA. Additionally, the testicular and sperm GSH levels were assessed based on the reduction of Ellman’s reagent [5,5΄-dithiobis (2-nitrobenzoic acid)] by the thiol groups of GSH to produce 2-nitro-S-mercaptobenzoic acid [32]. The product was measured spectrophotometrically at 412 nm. Protein estimation was performed based on the technique of Lowry et al. [33] using bovine serum albumin (BSA) as a standard.

Data analysis

The data were analyzed using the Mann-Whitney U and Kruskal-Wallis tests followed by Dunn’s multiple comparison test. A P = 0.05 was selected as the criterion for significance.

Results

Sperm FISH assay

The patterns of fluorescent signals in epididymal sperm visualized by the sperm FISH assay and examples of normal, five classes of disomic sperm and one class of diploid sperm are presented in Fig 2. The results of the sperm FISH assay are shown in Table 1. Dexrazoxane did not significantly increase the frequencies of disomic and diploid sperm at any of the doses tested. A significant increase in diploid and disomic sperm was induced by treatment with the two
highest doses of epirubicin compared to the control value. The dose-response curves for epirubicin-induced disomic and diploid sperm can be described by the linear equations $y = 0.021x + 0.029$ ($r^2 = 0.99$) and $y = 0.0144x + 0.015$ ($r^2 = 0.93$), respectively. In contrast, dexrazoxane pretreatment significantly reduced epirubicin-induced diploid and disomic sperm, and the higher dose of dexrazoxane induced greater amelioration ($P < 0.01$).

Spermatogonial metaphase chromosomal analysis

An example of spermatogonial metaphase with a structural chromosomal aberration is given in Fig 3. The results of spermatogonial metaphase chromosomal analysis (Fig 5) revealed that dexrazoxane alone did not affect spermatogonial chromosomes, confirming its lack of clastogenicity. On the other hand, epirubicin treatment increased the frequencies of spermatogonial chromosomal aberrations in a dose-dependent manner. The dose-response curve for epirubicin-induced spermatogonial chromosomal aberrations can be described by the linear equation $y = 6.0186x - 2.129$ ($r^2 = 0.98$). Conversely, pretreatment of mice with dexrazoxane prior to epirubicin injection significantly decreased the rates of metaphase chromosomal aberrations compared to those aberrations induced by epirubicin alone, and while the higher dose of dexrazoxane showed greater protection ($P < 0.01$).

Epididymal sperm analysis

Representative microscopic images of normal sperm and various abnormal shapes in epididymal sperm of mice are presented in Fig 4. As shown in Table 2, dexrazoxane treatment did not affect the parameters of sperm quality that were examined in this study. The fast moving sperm cells dramatically decreased in epirubicin-treated mice compared to that in vehicle control mice. In concert, the percentage of immotile sperm cells significantly increased in

Table 1. Sperm fluorescence in situ hybridization (FISH) of epididymal sperm from animals treated with indicated doses of dexrazoxane (Dex), epirubicin (Epi), or both.

| Treatment (mg/kg) | % Disomies       | % Diploidies      |
|------------------|------------------|-------------------|
| Control          | 0.052 ± 0.014    | 0.004 ± 0.005     |
| Dex (75)         | 0.060 ± 0.014    | 0.004 ± 0.005     |
| Dex (150)        | 0.062 ± 0.013    | 0.006 ± 0.005     |
| Epi (3)          | 0.068 ± 0.017    | 0.008 ± 0.004     |
| Epi (6)          | 0.092 ± 0.022    | 0.026 ± 0.008**   |
| Epi (12)         | 0.114 ± 0.018**  | 0.046 ± 0.011**   |
| Dex (75) + Epi (3)| 0.062 ± 0.004    | 0.008 ± 0.004     |
| Dex (75) + Epi (6)| 0.066 ± 0.025    | 0.018 ± 0.008     |
| Dex (75) + Epi (12)| 0.082 ± 0.014a  | 0.020 ± 0.007a    |
| Dex (150) + Epi (3)| 0.054 ± 0.011    | 0.006 ± 0.005     |
| Dex (150) + Epi (6)| 0.058 ± 0.010b  | 0.012 ± 0.008b    |
| Dex (150) + Epi (12)| 0.066 ± 0.011a  | 0.014 ± 0.008a    |

The frequencies of disomic and diploid sperm cells were assessed by DNA probes specific for the mouse sex chromosomes X and Y as well as the mouse chromosome 8 (an example of autosomal chromosomes and available at our laboratory) each labeled with a different color. Values are mean ± standard deviation (SD).

*$P < 0.05$

**$P < 0.01$ compared with vehicle control group (Kruskal-Wallis test followed by Dunn’s multiple comparisons test).

*a$ $P < 0.05$

b$P < 0.01$ compared with corresponding group treated with epirubicin alone (Mann-Whitney U-test).

doi:10.1371/journal.pone.0163703.t001
epirubicin-treated mice compared to that in vehicle control ($P < 0.01$). Furthermore, sperm count significantly decreased in mice injected with epirubicin alone ($P < 0.01$). Conversely, the changes in total sperm count and motility were reversed following dexrazoxane pretreatment. After epirubicin treatment, normal sperm morphology significantly decreased while total spermatozoa abnormalities significantly increased as compared to control animals ($P < 0.01$). On the other hand, pretreatment of animals with dexrazoxane significantly reduced the incidence of abnormal sperm cells compared to epirubicin exposure alone ($P < 0.05$).

8-OHdG and GSH levels

The results of testicular and sperm estimation of 8-OHdG and GSH are presented in Figs 6–9. As shown in Figs 6 and 7, treatment with dexrazoxane failed to induce any significant change in the levels of testicular and sperm 8-OHdG at the tested doses. A significant increase in

Table 2. Epididymal sperm analysis of animals treated with indicated doses of dexrazoxane (Dex), epirubicin (Epi), or both.

| Groups and chemicals (mg/kg) | Motility (%) | Morphology (%) | Sperm counts ($10^6$/ml) |
|-----------------------------|--------------|----------------|--------------------------|
|                             | Fast         | Slow          | Immotile                 | Normal        | Abnormal heads | Abnormal tails |
| Control                     | 64.2 ± 8.75  | 12.2 ± 3.03   | 23.2 ± 6.34              | 92.6 ± 2.02   | 4.00 ± 0.70    | 3.3 ± 1.55     | 62.2 ± 7.36   |
| Dex (150)                   | 60.6 ± 9.31  | 13.0 ± 2.91   | 26.4 ± 7.63              | 89.0 ± 4.06   | 5.86 ± 2.10    | 5.1 ± 2.01     | 54.4 ± 9.35   |
| Epi (12)                    | 34.8 ± 9.65* | 9.6 ± 2.30    | 55.6 ± 11.9**            | 78.6 ± 6.3**  | 10.18 ± 2.7**  | 12.1 ± 3.4**   | 29.2 ± 5.3**  |
| Dex (150) + Epi (12)        | 51.2 ± 10.7  | 13.4 ± 3.50   | 35.4 ± 11.1*             | 87.6 ± 4.0*   | 5.6 ± 2.0*     | 6.6 ± 2.4*     | 54.6 ± 6.6*   |

Values are mean ± standard deviation (SD).

* $P < 0.05$

** $P < 0.01$ compared with vehicle control group (Kruskal-Wallis test followed by Dunn’s multiple comparison test).

*$P < 0.05$

**$P < 0.01$ compared with group treated with epirubicin alone (Mann-Whitney $U$-test).
testicular and sperm 8-OHdG was observed in the epirubicin-treated mice compared to the solvent control groups (P<0.01). With regard to the animals treated with dexrazoxane before epirubicin, a weak protection in testis only was observed with 75 mg/kg of dexrazoxane (Fig 6). With 150 mg/kg pre-treatment, however, dexrazoxane produced a clear significant suppressive effect on the testicular and sperm 8-OHdG induced by epirubicin in comparison to the epirubicin alone (Figs 6 and 7).

As shown in Figs 8 and 9, there was no significant difference in the level of testicular and sperm GSH between the dexrazoxane-treated and control mice at any of the doses tested. The testicular and sperm GSH level observed in epirubicin-treated mice was significantly decreased as compared to the control value (P<0.01). In contrast, the epirubicin-induced decrease in testicular GSH was significantly increased in dexrazoxane-pretreated mice compared to the reported value with epirubicin treatment alone (Fig 8). Furthermore, mice pretreated with dexrazoxane showed a significant increase in sperm level of GSH compared to epirubicin-treated
mice (Fig 9). In addition, the values significantly differed from that of the testicular and sperm GSH after treatment with epirubicin alone and the higher dose of dexrazoxane induced greater improvement (P<0.01).

**Discussion**

Dexrazoxane is approved to treat cardiomyopathy and extravasation caused by anthracyclines [14, 15]. However, the effect of dexrazoxane on epirubicin-induced genetic alterations in germ cells has not yet been reported. Thus, the aim of this work was to ascertain whether co-administration of dexrazoxane would mitigate the epirubicin-induced genetic alterations in male germ cells. This study showed that dexrazoxane was not genotoxic at the tested doses. Furthermore, it protected the mouse germ cells against epirubicin-induced genetic alterations as detected by reduction in disomic and diploid sperm, spermatogonial chromosomal aberrations,
and sperm head abnormality. Total sperm number and motility were also restored following dexrazoxane pretreatment. In the present work, we attempted to elucidate the possible mechanisms underlying the anti-genotoxic action of dexrazoxane by examining its inhibition of free radical production. The data revealed that free radical production by epirubicin was significantly inhibited by pretreatment with dexrazoxane.

Human studies have demonstrated that several chemotherapy regimens increase the incidence of genetic alterations in germ cells, indicating that cancer patients undergoing treatment with these agents may be at a higher risk for abnormal reproductive outcomes [34]. Thus, it is of pertinent importance that male cancer patients be made aware that certain treatment regimens could result in diminished sperm quality or quantity due to an increase in genetic alterations in spermatogenic cells. In this study, epirubicin caused a dose-dependent increase in the percentage of diploid and disomic sperm cells, and the effect was significant at the two highest tested doses. Pretreatment of the animals with dexrazoxane significantly reduced epirubicin-induced diploid and disomic sperm and the higher dose induced greater protection. The results of our in vivo study on the effects of epirubicin treatment were in agreement with results of an earlier in vitro study with Chinese hamster cell cultures that showed epirubicin increased the hypodiploidy and hyperdiploidy of the cells [35]. Additionally, histological and flow cytometric analyses of mouse spermatogenesis displayed an increase in the coefficient of variation in the DNA histogram, a measure of aneuploidy, and an increase of diploid spermatids after epirubicin exposure [8].

Chromosomal aberrations are a significant event in tumorigenesis. A threshold level of DNA damage may exist that leads to an overload of the DNA repair mechanisms, and a significant increase in aberrant metaphases. In the present study, average chromosomal aberrations/100 metaphases in the vehicle control group was 4.5%, and this value corresponded well with that previously reported by Palo et al. [36] with the same age and strain of mice. Dexrazoxane alone failed to increase chromosomal aberrations in spermatogonial cells confirming its lack of clastogenicity. However, a significant increase in incidences of spermatogonial chromosomal aberrations was caused by treatment with all investigated doses of epirubicin. These findings were in concordance with previous observations that epirubicin induced structural chromosomal aberrations in both humans and animals [6, 37, 38]. In contrast, pretreatment of animals with dexrazoxane prior to the epirubicin injection significantly decreased the rates of clastogenic changes compared to epirubicin alone in a dose-dependent manner.

Disturbances in the reproductive system are a common adverse effect of chemotherapeutic agents [9, 39]. Treated male patients usually show poor sperm quality with increased abnormal sperm morphology and decreased total sperm number and motility. This high percentage of immotile or poorly motile sperm may not induce fertilization [40]. In the current study, dexrazoxane treatment did not affect the studied sperm quality parameters. On the other hand, percentages of sperm motility and count significantly decreased in epirubicin-treated mice. Moreover, epirubicin significantly increased the frequency of abnormal sperm while pretreatment with dexrazoxane ameliorated the decreased percentage of sperm count and motility. Additionally, the frequency of abnormal sperm was restored following dexrazoxane pretreatment. The decreased sperm quality after treatment with epirubicin was consistent with our previous results that exposure to epirubicin significantly increased aneuploid sperm [7]. Therefore, these findings are in agreement with previous results that patients with poor sperm quality show increased sperm diplody and disomy rates [41].

The precise mechanisms by which dexrazoxane protects against epirubicin-induced genetic alterations in germ cells are not fully understood. A possible explanation for this protection is that concurrent treatment with dexrazoxane scavenged free radicals produced by epirubicin before they could affect the DNA and cause genetic damage. In fact, the metabolism of
epirubicin is known to produce free radicals [42]. These free radicals may damage biological molecules including DNA and protein, eventually inducing cell damage, genetic alterations, and secondary tumors [43]. It has been reported that chromosomal aberrations and DNA damage in germ cells are closely related to male infertility and 8-OHdG is a sensitive biomarker of oxidative DNA damage caused by generation of free radicals in human germ cells [44]. In this study, to determine whether the anti-genotoxic effects of dexrazoxane were due to an improvement in scavenging of free radicals produced after exposure to epirubicin, GSH and 8-OHdG levels were assessed after the mice were injected with epirubicin, dexrazoxane, or both.

The results revealed that dexrazoxane pretreatment significantly decreased the epirubicin-induced testicular and sperm 8-OHdG levels, and inhibited the reduction in the testicular and sperm GSH. The improved GSH levels suggest that the protection by dexrazoxane may be mediated by modulation of cellular antioxidant levels. This finding is in concordance with previous experiments where dexrazoxane was reported to scavenge hydroxyl free radicals [45]. Moreover, dexrazoxane has a stronger intrinsic scavenging activity than typical antioxidants such as GSH, against not only hydroxyl free radicals, the typical free-radical product of redox reaction of iron complexes, but also peroxynitrite and peroxyl radicals. These findings demonstrate that the antioxidant effects of dexrazoxane are not solely dependent on iron chelation, although the latter may contribute to decreased iron-based free radical production [45, 46]. Consequently, the antioxidant property of dexrazoxane might be responsible for mitigating the genetic alterations induced by epirubicin in the germ cells.

Conclusion

The current study revealed that dexrazoxane was not genotoxic at the doses tested. Moreover, it may provide an efficient way to mitigate epirubicin-induced genetic damage in germ cells and reduce the associated risk for abnormal reproductive outcomes without decreasing epirubicin’s therapeutic efficiency, as demonstrated by its clinical effectiveness in averting both epirubicin-induced extravasation and cardiotoxicity. Performing in vitro fertilization studies that could track the rate of fertilization and development to blastocyst would be interesting and might provide more insights into the protective effect of dexrazoxane against reproductive toxicity induced by anthracyclines, and will be considered as a focus for our future study.

Acknowledgments

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group project No. RGP-120.

Author Contributions

Conceptualization: SMA SFA MAA AN OAA MMA SAB.
Data curation: SMA OAA MMA SAB.
Formal analysis: SMA SFA MAA AN.
Funding acquisition: SMA SFA SAB.
Investigation: SMA SFA MAA AN SAB.
Methodology: SMA SFA MAA AN SAB.
Project administration: SMA SFA SAB.
Resources: SMA SFA MAA AN SAB.
Software: SMA OAA MMA SAB.
Supervision: SMA OAA MMA SAB.
Validation: SMA MMA SAB.
Visualization: SMA SFA MAA AN OAA MMA SAB.
Writing – original draft: SMA SFA MAA AN OAA MMA SAB.
Writing – review & editing: SMA SFA MAA AN OAA MMA SAB.

References

1. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997; 54 Suppl 4:1–7. Epub 1997/01/01. PMID: 9361955
2. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC cancer. 2010; 10:337. Epub 2010/07/01. PubMed Central PMCID: PMC2907344. doi: 10.1186/1471-2407-10-337 PMID: 20587042
3. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical pharmacology. 1999; 57(7):727–41. Epub 1999/03/13. doi: 10.1016/S0006-2952(98)00307-4 PMID: 10075679
4. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2001; 4(5):303–13. Epub 2002/05/07. doi: 10.1054/drup.2001.0213 PMID: 11991684
5. Praga C, Bergh J, Bliss J, Bonnerette J, Cesana B, Coombes RC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(18):4179–91. Epub 2005/06/18. doi: 10.1200/JCO.2005.05.029 PMID: 15961765
6. Sen AK, Karakas E, Bilaloglu R. Genotoxic effect of epirubicin in mouse bone marrow in vivo. Zeitschrift fur Naturforschung C, Journal of biosciences. 2010; 65(3–4):211–7. Epub 2010/05/18. doi: 10.1515/znc-2010-3-408 PMID: 20469640
7. Attia SM, Ahmad SF, Okash RM, Bakheet SA. Aneugenic effects of epirubicin in somatic and germinal cells of male mice. PloS one. 2014; 9(10):e109942. Epub 2014/10/11. PubMed Central PMCID: PMC4193842. doi: 10.1371/journal.pone.0109942 PMID: 25303090
8. Hacker-Klom UB, Meistrich ML, Goehde W. Effect of doxorubicin and 4’-epi-doxorubicin on mouse spermatogenesis. Mutation research. 1986; 160(1):39–46. Epub 1986/03/01. doi: 10.1016/S0027-5107(86)80007-X PMID: 3456485
9. Attia SM. Mutagenicity of some topoisomerase II-interacting agents. Saudi Pharmaceutical Journal. 2008; 16:1–24.
10. Bishop JB, Delarco VL, Hassold T, Ferguson LR, Wyrobek AJ, Friedman JM. Aneuploidy in germ cells: etiologies and risk factors. Environmental and molecular mutagenesis. 1996; 28(3):159–66. Epub 1996/01/01. doi: 10.1002/(SICI)1098-2280(1996)28:3<159::AID-EM1>3.0.CO;2-9 PMID: 8908176
11. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nature reviews Genetics. 2012; 13(3):189–203. Epub 2012/01/25. doi: 10.1038/nrg3123 PMID: 22269907
12. Fritz B, Aslan M, Kalscheuer V, Ramsing M, Saar K, Fuchs B, et al. Low incidence of UPD in spontaneous abortions beyond the 5th gestational week. European journal of human genetics: EJHG. 2001; 9(12):910–6. Epub 2002/02/13. doi: 10.1038/sj.ejhg.5200741 PMID: 11840192
13. Tempest HG, Griffin DK. The relationship between male infertility and increased levels of sperm discrepancy. Cytogenetic and genome research. 2004; 107(1–2):83–94. Epub 2004/08/12. doi: 10.1159/000079575 PMID: 15305060
14. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England journal of medicine. 2004; 351(2):145–53. Epub 2004/07/13. doi: 10.1056/NEJMoa035153 PMID: 15247354
15. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2005;(1):CD003917. Epub 2005/01/28. doi: 10.1002/14651858.CD003917.pub2 PMID: 15674919

16. Diop NK, Vitellaro LK, Arnold P, Shang M, Marusak RA. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. Journal of inorganic biochemistry. 2000; 78(3):209–16. Epub 2000/05/11. doi: 10.1016/S0162-0134(00)00013-1 PMID: 10805177

17. Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovascular toxicology. 2002; 2(2):111–8. Epub 2002/09/25. doi: 10.1385/CT:2:2:111 PMID: 12271154

18. Pearlman M, Jendrioba D, Pagliaro L, Keyhani A, Liu B, Freireich EJ. Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leukemia research. 2003; 27(7):617–26. Epub 2003/05/11. doi: 10.1016/S0162-0134(03)00273-4 PMID: 12681361

19. Marty M, Espie M, Liombart A, Monnier A, Rapoport BL, Stahalova V, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2006; 17(4):614–22. Epub 2006/01/21. doi: 10.1093/annonc/mdj134 PMID: 16423847

20. Yan T, Deng S, Metzger A, Godtel-Armbrust U, Porter AC, Wojnowski L. Topoisomerase IIα-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Molecular cancer therapeutics. 2009; 8(5):1075–85. Epub 2009/05/07. doi: 10.1158/1535-7163.MCT-09-0139 PMID: 19417146

21. Hofland KF, Thougaard AV, Sehested M, Jensen PB. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(10):3915–24. Epub 2005/05/18. doi: 10.1188/1078-0432.CCR-04-2343 PMID: 15897593

22. Attia SM, Al-Anteet AA, Al-Rasheed NM, Al-Harbì MM. Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane. Cancer chemotherapy and pharmacology. 2009; 64(4):837–45. Epub 2009/02/03. doi: 10.1007/s00280-009-0934-8 PMID: 19184016

23. Bakheet SA, Attia SM, Al-Rasheed NM, Al-Harbì MM, Ashour AE, Korashy HM, et al. Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells. Mutagenesis. 2011; 26(4):533–43. Epub 2011/03/25. doi: 10.1093/mutage/ger013 PMID: 21430063

24. Attia SM, Ahmad SF, Saquib Q, Harisa GI, Al-Khedhaiy AA, Bakheet SA. Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells. Mutagenesis. 2016; 31(2):137–45. Epub 2015/09/25. doi: 10.1093/mutage/ger013 PMID: 26399706

25. Schmid TE, Attia S, Baumgartner A, Nuesse M, Adler ID. Effect of chemicals on the duration of male meiosis in mice detected with laser scanning cytometry. Mutagenesis. 2001; 16(4):339–43. Epub 2001/06/23. doi: 10.1093/mutage/16.4.339 PMID: 11420403

26. Attia SM, Schmid TE, Badary OA, Hamada FM, Adler ID. Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors. Mutation research. 2002; 520(1–2):1–13. Epub 2002/09/26. doi: 10.1016/S1383-5718(02)00079-7 PMID: 12297139

27. Adler I-D. Cytogenetic tests in mammals. In: Venitt S, and Parry JM., editor. Mutagenicity Testing: A Practical Approach: IRI Press, Oxford; 1984. p. 275–306.

28. Bender MA B J, Mitchell JB.. Bender MA, Bedford JS, Mitchell JB. Mechanisms of chromosomal aberration production. II. Aberrations induced by 5-bromodeoxyuridine and visible light. Mutation research. 1973; 20(3):403–16. Epub 2001/02/15. doi: 10.1016/0027-5107(73)90061-4 PMID: 4798362

29. Organization WH. World Health Organization Laboratory Manual for the Examination of Human Semen Samples and Sperm-Cervical Mucus Interaction. third ed ed. Cambridge, UK: Press Syndicate of the University of Cambridge; 1992. p. 23–7.

30. Wyrobek AJ, Bruce WR. Chemical induction of sperm abnormalities in mice. Proceedings of the National Academy of Sciences of the United States of America. 1975; 72(11):4425–9. Epub 1975/11/01. PubMed Central PMCID: PMC388734. doi: 10.1073/pnas.72.11.4425 PMID: 1060122

31. Attia SM. Influence of resveratrol on oxidative damage in genomic DNA and apoptosis induced by cisplatin. Mutation research. 2012; 741(1–2):22–31. Epub 2011/11/09. doi: 10.1016/j.mrgentox.2011.10.006 PMID: 22063162

32. Ellman GL. Tissue sulfhydryl groups. Archives of biochemistry and biophysics. 1959; 82(1):70–7. Epub 1959/05/01. doi: 10.1016/0003-9861(59)90090-6 PMID: 13650640
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. The Journal of biological chemistry. 1951; 193(1):265–75. Epub 1951/11/01. PMID: 14907713

34. Martin RH, McInnes B, Rademaker AW. Analysis of aneuploidy for chromosomes 13, 21, X and Y by multicolour fluorescence in situ hybridisation (FISH) in a 47,XY,Y male. Zygote. 1999; 7(2):131–4. Epub 1999/07/27. doi: 10.1017/S0967199499000489 PMID: 10418106

35. El-Mahdy Sayed Othman O. Cytogenetic effect of the anticancer drug epirubicin on Chinese hamster cell line in vitro. Mutation research. 2000; 468(2):109–15. Epub 2000/07/07. doi: 10.1016/S1383-5718(00)00047-4 PMID: 10882889

36. Palo AK, Sahoo D, Choudhury RC. Cytosine arabinoside-induced cytogenotoxicity in bone marrow and spermatogonial cells of mice and its potential transmission through the male germline. Mutation research. 2009; 673(1):29–36. Epub 2008/12/20. doi: 10.1016/j.mrgentox.2008.11.007 PMID: 19095079

37. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1992; 10(9):1444–51. Epub 1992/09/01. PMID: 1517787

38. Silva LM, Takahashi CS, Carrara HH. Study of chromosome damage in patients with breast cancer treated by two antineoplastic treatments. Teratogenesis, carcinogenesis, and mutagenesis. 2002; 22(4):257–69. Epub 2002/07/12. doi: 10.1002/tcm.10019 PMID: 12111710

39. Simon B, Lee SJ, Partridge AH, Runowicz CD. Preserving fertility after cancer. CA: a cancer journal for clinicians. 2005; 55(4):211–28; quiz 63–4. Epub 2005/07/16. doi: 10.3322/canjclin.55.4.211 PMID: 16020423

40. Cavallini G. Male idiopathic oligoasthenoteratozoospermia. Asian journal of andrology. 2006; 8(2):143–57. Epub 2006/02/24. doi: 10.1111/j.1745-7262.2006.00123.x PMID: 16491265

41. Collodel G, Capitani S, Baccetti B, Pammolli A, Moretti E. Sperm aneuploidies and low progressive motility. Human reproduction. 2007; 22(7):1893–8. Epub 2007/06/19. doi: 10.1093/humrep/dem099 PMID: 17575282

42. Granqvist K, Henriksson R. Doxorubicin and epirubicin iron-induced generation of free radicals in vitro. A comparative study. Bioscience reports. 1987; 7(8):653–8. Epub 1987/08/01. PMID: 3480764

43. Attia SM. Deleterious effects of reactive metabolites. Oxidative medicine and cellular longevity. 2010; 3(4):238–53. Epub 2010/10/26. PubMed Central PMCID: PMC2952084. doi: 10.4161/oxim.3.4.13246 PMID: 20972370

44. Shen H, Ong C. Detection of oxidative DNA damage in human sperm and its association with sperm function and male infertility. Free radical biology & medicine. 2000; 28(4):529–36. Epub 2000/03/17. doi: 10.1016/S0891-5849(99)00234-8 PMID: 10719234

45. Junjing Z, Yan Z, Baolu Z. Scavenging effects of dexrazoxane on free radicals. Journal of clinical biochemistry and nutrition. 2010; 47(3):238–45. Epub 2010/11/26. PubMed Central PMCID: PMC2966934. doi: 10.3164/jcbin.10-64 PMID: 21103033

46. Galetta F, Franzoni F, Cervetti G, Regoli F, Fallahi P, Tocchini L, et al. In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomedicine & pharmacotherapy = Biomedicine & pharmacotherapy. 2010; 64(4):259–63. Epub 2009/11/26. doi: 10.1016/j.biopha.2009.06.018 PMID: 19932589